Fri, Jun 3, 6:59 AM, Zacks
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
Tue, May 17, 6:04 AM, Zacks
Myriad Genetics Brings myVectra Web Portal for RA Patients
Myriad's (MYGN) myVectra portal will offer easy access for its users to their Vectra DA test score, which in turn would keep the concerned RA patients better informed about the current status of their disease.